查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1733219

胶囊内视镜市场（按配件、产品、应用和地区划分），2026 年至 2032 年

Capsule Endoscopy Market By Accessories (Wireless Capsule, Workstation and Receiver), By Product (Small Bowel, Esophageal), Application (Crohn's Disease, OGIB (Obscure Gastrointestinal Bleeding)), & Region for 2026-2032
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

胶囊内视镜市场评估（2026-2032）

克隆氏症和消化道出血等疾病病例的增加推动了胶囊内视镜检查的普及。胶囊设计和成像技术的创新正在提高诊断准确性和患者体验，推动市场规模在 2024 年超过 2.923 亿美元，到 2032 年达到约 9.7156 亿美元的估值。

这一点，加上人们对胃肠道健康和可用诊断选项的认识不断提高，正在刺激胶囊内视镜的采用。人们对非侵入性诊断方法的日益增长的偏好推动了患者对胶囊内视镜的接受和使用，使市场在 2026 年至 2032 年期间的复合年增长率达到 16.20%。

胶囊内视镜市场定义/概述

胶囊内视镜检查是一种微创诊断程序，透过吞下锭剂大小的小型相机来拍摄胃肠道（GI）的移动影像。该设备通常包含一个光源和一个摄像头，可将影像无线传输到外部记录设备。此技术可详细观察传统内视镜难以到达的消化道区域，例如小肠。

胶囊内视镜主要用于诊断消化道出血、克隆氏症和小肠肿瘤。这对于出现不明原因胃肠道症状的患者尤其有益，因为它可以全面检查小肠，而小肠中的许多病变可能被忽略。该测试通常是安全的、非侵入性的并且不需要镇静，因此对许多患者来说是一个有吸引力的选择。

胃肠道疾病的日益普及将如何促进胶囊内视镜检查的普及？

胃肠道疾病盛行率的上升是胶囊内视镜市场发展的主要驱动力。根据美国国家糖尿病、消化和肾臟疾病研究所的数据，美国约有 6,000 万至 7,000 万人患有消化系统疾病。不断增长的患者群体正在推动对微创诊断工具的需求。胶囊内视镜检查提供了一种无痛且有效的方法来观察整个小肠，而使用传统的内视镜技术很难检查。 2024 年 3 月，Medtronic宣布推出新款 PillCam(TM) SB4 系统，具有增强的影像处理功能和更长的电池寿命。

胶囊内视镜系统的技术进步正在推动市场成长。更高解析度的摄影机、更长的电池寿命和人工智慧辅助影像分析等技术创新正在提高诊断准确性并扩大胶囊内视镜的应用范围。这些发展对于小肠肿瘤和不明原因的消化道出血的检测尤其重要。世界卫生组织 (WHO) 报告称，2020 年大肠癌将成为全球第三大常见癌症，新增病例数将达到 193 万人。为了满足这一日益增长的需求，Olympus Corporation于 2024 年 2 月宣布推出采用基于 AI 的病变检测演算法的下一代胶囊内视镜平台。

向基于价值的医疗保健的转变和远端医疗的日益普及正在推动胶囊内视镜市场向前发展。胶囊内视镜检查是一种比传统内视镜检查更具成本效益的替代方法，可减少住院和麻醉的需要。美国医疗保险和医疗补助服务中心报告称，在新冠疫情期间，远端医疗就诊量增加了 63 倍，从 2019 年的约 84 万次增加到 2020 年的 5,270 万次。这一趋势仍在持续，为远端胶囊内视镜检查创造了机会。

胶囊内视镜检查的报销选择有限是否会限制市场成长？

由于该技术高成本，胶囊内视镜市场面临重大限制。除了所需的影像处理和读取软体外，设备本身也很昂贵。这种经济负担通常会限制病患和医疗机构的可近性，特别是在医疗预算紧张的开发中地区。高成本也阻碍了医疗保健提供者采用这项技术，从而限制了整体市场的成长。

另一个阻碍因素是胶囊内视镜检查的报销选择相对有限。许多保险公司不承担全部费用，这可能会阻碍患者和医生选择这种诊断工具。由于缺乏标准化的报销指南，情况变得更加复杂，医疗保健提供者很难证明胶囊内视镜检查的成本与传统方法相比是合理的。

此外，数据管理和分析方面的技术挑战也阻碍了市场的发展。胶囊内视镜产生的大量数据需要复杂的软体进行处理和解释。然而，目前的影像分析能力和诊断准确性可能不一致，导致人们担心漏诊和需要后续程序。这种不确定性可能会使医疗保健专业人员不再依赖胶囊内视镜作为主要诊断工具，从而影响市场采用。

目录

第一章全球胶囊内视镜市场介绍

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章全球胶囊内视镜市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

第五章 全球胶囊内视镜市场（依配件）

  • 概述
  • 无线胶囊
  • 工作站和接收器

第六章全球胶囊内视镜市场（依产品）

  • 概述
  • 小肠
  • 食道
  • 冒号

第七章全球胶囊内视镜市场（按应用）

  • 概述
  • 克隆氏症
  • OGIB（不明原因消化道出血）
  • 小肠肿瘤
  • 其他的

8. 全球胶囊内视镜市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区
    • 拉丁美洲
    • 中东和非洲

第九章全球胶囊内视镜市场的竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第十章 公司简介

  • CapsoVision
  • Given Imaging
  • IntroMedic Co., Ltd.
  • RF System lab
  • Chongqing Jinshan Science & Technology（Group）Co., Ltd
  • Olympus Corporation
  • Fujifilm Holding Corporation

第十一章 重大进展

  • 产品发布/开发
  • 合併与收购
  • 业务扩展
  • 伙伴关係与合作

第十二章 附录

  • 相关调查
简介目录
Product Code: 33489

Capsule Endoscopy Market Valuation - 2026-2032

Rising cases of conditions like Crohn's disease and gastrointestinal bleeding is propelling the adoption of capsule endoscopy. Innovations in capsule design and imaging technology enhance diagnostic accuracy and patient experience is driving the market size surpass USD 292.3 Million valued in 2024 to reach a valuation of around USD 971.56 Million by 2032.

In addition to this, increased awareness about gastrointestinal health and available diagnostic options is spurring up the adoption of capsule endoscopy. The rising preference for non-invasive diagnostic methods drives patient acceptance and usage of capsule endoscopy is enabling the market grow at a CAGR of 16.20% from 2026 to 2032.

Capsule Endoscopy Market: Definition/ Overview

Capsule endoscopy is a minimally invasive diagnostic procedure that involves swallowing a small, pill-sized camera that captures images of the gastrointestinal (GI) tract as it travels through. The device, typically equipped with a light source and camera, transmits images wirelessly to an external recorder. This technique allows for detailed visualization of areas of the GI tract that are difficult to reach with traditional endoscopic methods, such as the small intestine.

Capsule endoscopy is primarily used for diagnosing conditions such as gastrointestinal bleeding, Crohn's disease, and small bowel tumors. It is particularly beneficial for patients who experience unexplained GI symptoms, as it provides a comprehensive view of the small intestine, where many pathologies may go unnoticed. The procedure is generally safe, non-invasive, and does not require sedation, making it an attractive option for many patients.

How will Rising Prevalence of Gastrointestinal Disorders Increase the Adoption of Capsule Endoscopy?

The rising prevalence of gastrointestinal disorders is a key driver of the capsule endoscopy market. According to the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 60 to 70 million people in the United States are affected by digestive diseases. This increasing patient population has led to a growing demand for minimally invasive diagnostic tools. Capsule endoscopy offers a painless and efficient method for visualizing the entire small intestine, which is challenging to examine using traditional endoscopic techniques. In March 2024, Medtronic announced the launch of their new PillCam(TM) SB4 system, featuring enhanced imaging capabilities and improved battery life.

Technological advancements in capsule endoscopy systems are fueling market growth. Innovations such as higher resolution cameras, longer battery life, and artificial intelligence-assisted image analysis are improving diagnostic accuracy and expanding the applications of capsule endoscopy. These developments are particularly crucial for detecting small bowel tumors and obscure gastrointestinal bleeding. The World Health Organization reported that colorectal cancer was the third most common cancer worldwide in 2020, with 1.93 million new cases. In response to this growing need, Olympus Corporation unveiled its next-generation capsule endoscopy platform in February 2024, incorporating AI-powered lesion detection algorithms.

The shift towards value-based healthcare and the increasing adoption of telemedicine are driving the capsule endoscopy market forward. Capsule endoscopy offers a cost-effective alternative to traditional endoscopic procedures, reducing the need for hospital stays and anesthesia. The Centers for Medicare & Medicaid Services reported that telehealth visits increased by 63-fold during the COVID-19 pandemic, from approximately 840,000 in 2019 to 52.7 million in 2020. This trend has persisted, creating opportunities for remote capsule endoscopy procedures.

Will Limited Reimbursement Options Available for Capsule Endoscopy Restrain the Market Growth?

The capsule endoscopy market faces significant limitations due to the high costs associated with the technology. The devices themselves, along with the necessary imaging and interpretation software, can be expensive. This financial burden often restricts accessibility for patients and healthcare facilities, particularly in developing regions where healthcare budgets are tighter. The high cost can lead to hesitancy among providers to adopt the technology, limiting its overall market growth.

Another restraint is the relatively limited reimbursement options available for capsule endoscopy procedures. Many insurance providers do not fully cover the costs, which can discourage both patients and physicians from opting for this diagnostic tool. The lack of standardized guidelines for reimbursement further complicates the situation, making it challenging for healthcare providers to justify the expense of capsule endoscopy compared to traditional methods.

Additionally, the market is hindered by technological challenges related to data management and analysis. The vast amount of data generated by capsule endoscopes requires sophisticated software for processing and interpretation. However, the current capabilities for image analysis and diagnostic accuracy can be inconsistent, leading to concerns about missed diagnoses or the need for follow-up procedures. This uncertainty can deter healthcare professionals from relying on capsule endoscopy as a primary diagnostic tool, impacting market adoption.

Category-Wise Acumens

Will Rise in Adoption of Wireless Capsule Endoscopy Bolster Capsule Endoscopy Market Growth?

Wireless capsule endoscopy has emerged as the dominant technology in the capsule endoscopy market, revolutionizing gastrointestinal diagnostics. This non-invasive method allows for comprehensive visualization of the small intestine, which is challenging to examine using traditional endoscopic techniques. The U.S. Food and Drug Administration (FDA) reports that since the approval of the first wireless capsule endoscopy system in 2001, over 2 million procedures have been performed worldwide. The technology's ability to provide high-resolution images while minimizing patient discomfort has led to its widespread adoption.

The wireless capsule's dominance is further reinforced by its expanding applications beyond small bowel examination. Recent advancements have enabled its use in esophageal and colon screenings, broadening its clinical utility. According to the National Institute of Diabetes and Digestive and Kidney Diseases, colorectal cancer is the third most common cancer in both men and women in the United States, with an estimated 151,030 new cases in 2022. This prevalence underscores the importance of effective screening tools like wireless capsule endoscopy.

Which Factors Enhance the Use of Capsule Endoscopy to Diagnose Obscure Gastrointestinal Bleeding (OGIB)?

Obscure Gastrointestinal Bleeding (OGIB) has emerged as the dominant application in the capsule endoscopy market, driving significant growth and innovation. OGIB, defined as persistent or recurrent bleeding from the gastrointestinal tract with no identifiable source through conventional endoscopy, presents a unique diagnostic challenge that capsule endoscopy is uniquely positioned to address. According to the National Institute of Diabetes and Digestive and Kidney Diseases, OGIB accounts for approximately 5% of all gastrointestinal bleeding cases, with the small bowel being the most common source. Capsule endoscopy's ability to visualize the entire small intestine has made it an invaluable tool in diagnosing OGIB.

The prevalence of OGIB and its impact on patient quality of life have spurred technological advancements in capsule endoscopy systems. These improvements include higher resolution cameras, longer operating times, and artificial intelligence-assisted image analysis, all aimed at enhancing the detection of subtle bleeding sources. The American Journal of Gastroenterology reported that capsule endoscopy has a diagnostic yield of up to 67% in patients with OGIB, significantly higher than other diagnostic modalities. This high diagnostic yield has solidified capsule endoscopy's position as the gold standard for OGIB diagnosis.

Country/Region-wise Acumens

Will Presence Of Major Market Players in North America Fuel the Capsule Endoscopy Market Growth?

North America dominates the capsule endoscopy market, driven by a high prevalence of gastrointestinal disorders and advanced healthcare infrastructure. The region's leadership is underpinned by early adoption of innovative medical technologies and a robust reimbursement landscape. According to the Centers for Disease Control and Prevention (CDC), colorectal cancer is the third most common cancer in both men and women in the United States, with 151,030 new cases reported in 2022. This high incidence rate has fueled demand for advanced diagnostic tools like capsule endoscopy. In January 2024, Medtronic, a key player in the North American market, launched its next-generation PillCam(TM) SB4 system, featuring improved image resolution and a longer battery life, further solidifying the region's dominance in capsule endoscopy technology.

The presence of major market players and ongoing research and development activities contribute significantly to North America's leading position. The region boasts a high concentration of key manufacturers, fostering innovation and competitive pricing. The U.S. Food and Drug Administration (FDA) reported that since the first capsule endoscopy system approval in 2001, over 2 million procedures have been performed in the United States alone. This high adoption rate reflects the region's advanced healthcare system and willingness to embrace new technologies. In March 2024, Olympus Corporation announced the opening of a new research and development center in California, focusing on AI-powered image analysis for capsule endoscopy, highlighting the region's continued investment in advancing this technology.

Will Improving Access to Advanced Medical Technologies Enhance Adoption of Capsule Endoscopy in Asia Pacific?

The Asia Pacific region is experiencing rapid growth in the capsule endoscopy market, driven by increasing healthcare expenditure, rising awareness of gastrointestinal diseases, and improving access to advanced medical technologies. Countries like China, Japan, and India are at the forefront of this expansion, with their large populations and growing middle class contributing to increased demand for minimally invasive diagnostic tools. According to the World Health Organization, the incidence of colorectal cancer in Asia is expected to increase by 60% by 2030, reaching 1.5 million new cases annually. This alarming projection has spurred investment in early detection technologies.

Technological advancements and localization efforts by key market players are fueling the rapid growth of capsule endoscopy in Asia Pacific. The region's tech-savvy population and strong manufacturing capabilities have created a fertile ground for innovation in medical devices. The Indian Council of Medical Research reported that in 2023, there was a 15% increase in the adoption of capsule endoscopy procedures across major Indian hospitals compared to the previous year. This trend reflects the growing acceptance of the technology among healthcare providers and patients alike.

Competitive Landscape

The capsule endoscopy market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the capsule endoscopy market include:

  • Given Imaging (Medtronic)
  • Olympus Corporation
  • Pentax Medical
  • FujiFilm Corporation
  • Siemens Healthineers
  • Check-Cap Ltd.
  • IntroMedic Co., Ltd.
  • Capsovision, Inc.
  • Medtronic
  • BSC (Boston Scientific Corporation)
  • Hoya Corporation
  • Echosens
  • Endocapsule (Olympus)
  • Motus GI Holdings, Inc.
  • STERIS plc
  • C2N Diagnostics
  • Medtronic (Acquisition of Given Imaging)
  • VGI Health Technology
  • Lumendi
  • Kallistem

Latest Developments

  • In September 2023, Medtronic announced the launch of its latest capsule endoscopy system, featuring advanced imaging technology that improves diagnostic accuracy for gastrointestinal disorders.
  • In August 2023, a collaborative study published in the Journal of Gastroenterology highlighted the increasing efficacy of capsule endoscopy in detecting early-stage colorectal cancer, leading to growing demand in the market.

Capsule Endoscopy Market, By Category

  • Accessories:
  • Wireless Capsule
  • Workstation and Receiver
  • Product:
  • Small Bowel
  • Esophageal
  • Colon
  • Application:
  • Crohn's Disease
  • OGIB (Obscure Gastrointestinal Bleeding)
  • Small Intestine Tumor
  • Region:
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL CAPSULE ENDOSCOPY MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL CAPSULE ENDOSCOPY MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL CAPSULE ENDOSCOPY MARKET, BY ACCESSORIES

  • 5.1 Overview
  • 5.2 Wireless Capsule
  • 5.3 Workstation and Receiver

6 GLOBAL CAPSULE ENDOSCOPY MARKET, BY PRODUCT

  • 6.1 Overview
  • 6.2 Small Bowel
  • 6.3 Esophageal
  • 6.4 Colon

7 GLOBAL CAPSULE ENDOSCOPY MARKET, BY APPLICATION

  • 7.1 Overview
  • 7.2 Crohn's Disease
  • 7.3 OGIB (Obscure Gastrointestinal Bleeding)
  • 7.4 Small Intestine Tumor
  • 7.5 Others

8 GLOBAL CAPSULE ENDOSCOPY MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East & Africa

9 GLOBAL CAPSULE ENDOSCOPY MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 CapsoVision
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Given Imaging
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 IntroMedic Co., Ltd.
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 RF System lab
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Chongqing Jinshan Science & Technology (Group) Co., Ltd
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Olympus Corporation
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Fujifilm Holding Corporation
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 Appendix

  • 12.1 Related Research